Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
about
Convergence of Cancer Metabolism and Immunity: an Overview.The evolution into personalized therapies in pancreatic ductal adenocarcinoma: challenges and opportunities.Exploiting Metabolic Vulnerabilities of Cancer with Precision and Accuracy.Upper gastrointestinal malignancies in 2017: current perspectives and future approaches.Pancreatic Cancer: Molecular Characterization, Clonal Evolution and Cancer Stem Cells.Therapeutic potential of CPI-613 for targeting tumorous mitochondrial energy metabolism and inhibiting autophagy in clear cell sarcoma.
P2860
Safety and tolerability of the first-in-class agent CPI-613 in combination with modified FOLFIRINOX in patients with metastatic pancreatic cancer: a single-centre, open-label, dose-escalation, phase 1 trial.
description
2017 nî lūn-bûn
@nan
2017 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Safety and tolerability of the ...... ose-escalation, phase 1 trial.
@ast
Safety and tolerability of the ...... ose-escalation, phase 1 trial.
@en
type
label
Safety and tolerability of the ...... ose-escalation, phase 1 trial.
@ast
Safety and tolerability of the ...... ose-escalation, phase 1 trial.
@en
prefLabel
Safety and tolerability of the ...... ose-escalation, phase 1 trial.
@ast
Safety and tolerability of the ...... ose-escalation, phase 1 trial.
@en
P2093
P2860
P1433
P1476
Safety and tolerability of the ...... ose-escalation, phase 1 trial.
@en
P2093
Amy Cameron
Angela Alistar
Asela R Boteju
Bonny B Morris
Boris Pasche
Clancy Clark
Gregory Hawkins
Guangxu Jin
Heidi D Klepin
John J Migliano
P2860
P304
P356
10.1016/S1470-2045(17)30314-5
P50
P577
2017-05-08T00:00:00Z